Hepatocellular Carcinoma in Noncirrhotic Liver with Glycogenotic Foci: Basic Science Meets Genomic Medicine

Abstract

During the past decade, the application of genomic analysis to liver tumors has provided extensive data concerning tumor phenotypes, signatures, outcomes, and prognosis. In this report the authors describe a middle-aged man without known risk factors for liver disease or hepatocellular carcinoma (HCC) who developed a 19-cm HCC in his right lobe. The underlying liver was normal histologically except for multifocal glycogenotic foci similar to those found in experimental chemical carcinogenesis. Precision genomic analysis of this tumor disclosed five alterations with amplifications of genes CCNE1, FGF3 and FGF4, MYCL1, and ARID1A. The roles of these gene mutations and their potential effects in carcinogenesis in this case are discussed.

Keywords

glycogenotic foci - glycogenosis - carcinogenesis - genomic medicine - hepatocellular carcinoma - ARID1A - FGF3 - FGF4 - CCNE1 - MYCL1 - noncirrhotic liver

• References

• 1 Bannasch P. Glycogenotic hepatocellular carcinoma with glycogen-ground-glass hepatocytes: a heuristically highly relevant phenotype. World J Gastroenterol 2012; 18 (46) 6701-6708
• 2 Bannasch P. Hepatocellular glycogenosis and hepatic neoplasms. Toxicol Pathol 2010; 38 (6) 1000-1002
• 3 Bannasch P, Jahn U, Hacker H , et al. Focal hepatic glycogenosis. Int J Oncol 1997; 10 (2) 261-268
• 4 Nehrbass D, Klimek F, Bannasch P. Overexpression of insulin receptor substrate-1 emerges early in hepatocarcinogenesis and elicits preneoplastic hepatic glycogenosis. Am J Pathol 1998; 152 (2) 341-345
• 5 Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105 (1) 65-75
• 6 Bralet MP, Régimbeau JM, Pineau P , et al. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000; 32 (2) 200-204
• 7 Ngo DC, Ververis K, Tortorella SM, Karagiannis TC. Introduction to the molecular basis of cancer metabolism and the Warburg effect. Mol Biol Rep 2015; 42 (4) 819-823
• 8 Bianchi L. Glycogen storage disease I and hepatocellular tumours. Eur J Pediatr 1993; 152 (Suppl. 01) S63-S70
• 9 Fitzpatrick E, Cotoi C, Quaglia A, Sakellariou S, Ford-Adams ME, Hadzic N. Hepatopathy of Mauriac syndrome: a retrospective review from a tertiary liver centre. Arch Dis Child 2014; 99 (4) 354-357
• 10 Torbenson M, Chen Y-Y, Brunt E , et al. Glycogenic hepatopathy: an underrecognized hepatic complication of diabetes mellitus. Am J Surg Pathol 2006; 30 (4) 508-513
• 11 Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology 2015; 149 (5) 1226-1239.e4
• 12 Schulze K, Imbeaud S, Letouzé E , et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet 2015; 47 (5) 505-511
• 13 Yasui K, Arii S, Zhao C , et al. TFDP1, CUL4A, and CDC16 identified as targets for amplification at 13q34 in hepatocellular carcinomas. Hepatology 2002; 35 (6) 1476-1484
• 14 Arao T, Ueshima K, Matsumoto K , et al. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma. Hepatology 2013; 57 (4) 1407-1415
• 15 Sun M, Eshleman JR, Ferrell LD , et al. An early lesion in hepatic carcinogenesis: loss of heterozygosity in human cirrhotic livers and dysplastic nodules at the 1p36-p34 region. Hepatology 2001; 33 (6) 1415-1424
• 16 Abe H, Hayashi A, Kunita A , et al. Altered expression of AT-rich interactive domain 1A in hepatocellular carcinoma. Int J Clin Exp Pathol 2015; 8 (3) 2763-2770
• 17 Hart AW, Baeza N, Apelqvist A, Edlund H. Attenuation of FGF signalling in mouse β-cells leads to diabetes. Nature 2000; 408 (6814) 864-868